Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Impfstoff gegen Varizellen  (1)
  • Key wordsHaemophilus influenzae type b  (1)
  • 1
    Electronic Resource
    Electronic Resource
    Gegen Varizellen impfen? (1999)
    Springer
    Monatsschrift Kinderheilkunde 147 (1999), S. 626-633 
    Details
    ISSN: 1433-0474
    Keywords: Schlüsselwörter Varizellen ; Impfstoff gegen Varizellen ; Routineprüfung ; Indikationsimpfung ; Anwendung in Deutschland ; Key words Varicella ; Varicella vaccine ; Routine vaccination ; Vaccination of risk groups use in Germany
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary Background: For more than ten years, a live, attenuated varicella vaccine is available. With the licensure of a temperature stable vaccine preparation in Germany in 1994, a cost reduction from DM 510,– to DM 99.50 was achieved with a general vaccine availability independent of special cooling requirements. In the United States, in Japan and in Southern Korea varicella vaccine is already in use for routine vaccination in the second year of life. In contrast, in Germany the recommendation for VZV-vaccination is restricted to patients at increased risk for varicella complications as well as for regular intimate contacts of such persons. Discussion: In this article a short review of varicella and zoster is given, the characteristics of the VZV-vaccine are described and the options for future use in Germany are discussed.
    Notes: Zusammenfassung Hintergrund: Seit mehr als 10 Jahren ist ein Lebendimpfstoff gegen Varizellen verfügbar. Mit Zulassung eines temperaturstabilen Präparats in Deutschland im Jahr 1994 sind die Kosten für eine Dosis von rund DM 510,– auf DM 99,50 gesunken, eine generelle Verfügbarkeit ist heute gewährleistet. In den Vereinigten Staaten von Amerika, in Japan und in Südkorea wird dieser Impfstoff routinemäßig und universell im Kleinkindesalter appliziert, in Deutschland dagegen wird er lediglich als Indikationsimpfung für Risikogruppen empfohlen. Diskussion: In diesem Artikel wird kurz die Varicella-Zoster-Virus(VZV)-Infektion beschrieben, danach werden die Charakteristika des VZV-Impfstoffs dargestellt. Die verschiedenen Möglichkeiten der Anwendung des VZV-Impfstoffs und deren jeweilige Folgen in Deutschland werden diskutiert.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s001120050472
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations (1998)
    Springer
    European journal of pediatrics 157 (1998), S. 208-214 
    Details
    ISSN: 1432-1076
    Keywords: Key wordsHaemophilus influenzae type b ; Acellular pertussis ; Vaccination ; PRP-tetanus ; Diphtheria
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract With an increasing number of new vaccines available for routine childhood immunization, combination vaccines are needed in order to maintain or achieve a high compliance with recommended immunization programmes. In a prospective, randomized, comparative, multi-centre study, 822 healthy infants were enrolled to receive three doses of either a candidate or a commercially available Haemophilus influenzae type b (Hib) vaccine concomitantly with diphtheria-, tetanus- acellular pertussis (DTaP) vaccine. Study subjects were randomly allocated to one of the following groups: (1) separate, or (2) mixed injection of DTaP and candidate Hib vaccine, or (3) separate injection of DTaP and commercial Hib vaccine. One year later the first 189 study subjects received either separate or mixed injections of the same Hib and DTaP vaccines as booster doses. Evaluation of reactogenicity was based on diary cards completed by parents. Immunogenicity was documented by measuring IgG antibody concentrations in serum samples taken before and 4 weeks after primary and booster vaccination. No serious adverse events occurred and most local and systemic reactions were mild to moderate. Booster doses were more reactogenic than primary doses with all groups. Antibody concentrations against pertussis antigens were similar to those seen with DTaP alone. All but one subject had protective antibody concentrations against diphtheria and tetanus. Primary immune response to the Hib vaccine was significantly lower in the group receiving the mixed Hib-DTaP vaccine, however, ≥95% of vaccinees had anti-Hib antibody concentrations ≥0.15 μg/ml and there was a marked booster response (〉100-fold) in all groups. Conclusions Mixing DTaP and Hib vaccines for primary immunization caused a decrease in anti-Hib antibody response, although after primary immunization as after booster doses, all subjects showed antibody concentrations considered to be protective for invasive Hib disease. Mixing of the vaccines did not result in increased reactogenicity.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s004310050797
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...